Drug Profile
Research programme: IkappaB kinase beta inhibitors - Bayer
Alternative Names: BAY 65 5811Latest Information Update: 24 Mar 2010
Price :
$50
*
At a glance
- Originator Bayer HealthCare
- Class Small molecules
- Mechanism of Action I-kappa B kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Asthma; Cancer; Hypersensitivity